NICHOLE HORN: Open Payments
NPI 1467682385 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,258 in 230 payments from 34 companies in 2025. Trend: 2023 $3,874 · 2024 $3,746 · 2025 $4,258
Food & beverage: $4,126Education: $132
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $655 |
| UCB, Inc. | 21 | $376 |
| Alexion Pharmaceuticals, Inc. | 10 | $218 |
| ACADIA Pharmaceuticals Inc | 14 | $208 |
| Neurocrine BioSciences, Inc. | 9 | $205 |
| Teva Pharmaceuticals USA, Inc. | 12 | $199 |
| Novartis Pharmaceuticals Corporation | 9 | $195 |
| ARGENX US, INC. | 9 | $179 |
| SK Life Science, Inc. | 7 | $174 |
| PFIZER INC. | 13 | $173 |
Products named: BOTOX, QULIPTA, ULTOMIRIS, NUPLAZID, INGREZZA, KESIMPTA, AUSTEDO XR, Zilbrysq.
Industry payments across MS — which companies pay providers there.
